Acceleron Pharma, Inc.;Ludwig Institute for Cancer Research Ltd.
发明人:
Grinberg, Asya,Seehra, Jasbir,Pearsall, Robert Scott,Pietras, Kristian,Kumar, Ravindra,Knopf, John
申请号：
AU2019232838
公开号：
AU2019232838A1
申请日:
2019.09.18
申请国别(地区):
AU
年份:
2019
代理人:
摘要：
#$%^&*AU2019232838A120191010.pdf#####H: rbr lnterwoven NRPortblDCC RBR 16278684_I.doex-1l/01/2018 ABSTRACT METHODS AND COMPOSITIONS FOR MODULATING ANGIOGENESIS AND PERICYTE COMPOSITION 5 In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALKI) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. Additionally, the disclosure demonstrates that 10 inhibitors of ALK1 may be used to increase pericyte coverage in vascularized tissues, including tumors and the retina. The disclosure also identifies ligands for ALKI and demonstrates that such ligands have pro-angiogenic activity, and describes antibodies that inhibit receptor-ligand interaction
